All News

Kevin gets philosophical, sharing deeply wrought insights in a manner that, just possibly, might actually make sense

A new study has uncovered notable disparities in uptake of adjuvant breast cancer therapies in the Appalachian region of the United States, a finding that suggests targeted intervention strategies may help to improve outcomes for this population of women.

Oncology clinicians and practices need to do a better job of engaging patients more fully in their care planning and make patient-reported outcomes an integral part of cancer treatment research.

People want to help, so go ahead and ask for help. Cancer is not a one-person job.

New Year's Resolutions tend to get lost in the shuffle as the year progresses. Looking back at my list, halfway through the year, I see my cancer fighting soldiers are still in my corner.

Maurie Markman urges patients with ovarian cancer who have undergone surgery to speak with their gynecologic oncologist and see if IP therapy is right for them.

Illness is a solitary endeavor, but you still need people to ground you and give you strength as you move through it and face tests, treatments and recovery.

New diagnoses of prostate cancer have declined nearly 30 percent, a study has found, since the U.S. Preventive Services Task Force discouraged the routine use of prostate-specific antigen testing in 2011.

Taking flu shots and other preventive vaccines before cancer treatment is a good idea, but patients should know when to pursue the injections and when to hold off.

Women who take birth control pills may be protecting themselves against endometrial cancer -- and not just during the years that they use these medications, but in the long term.

Even in a period of change, I still look at my dear husband frozen in time due to this disease.

Two-time cancer survivor and clutter clearing trainer vents about time management problems with an awareness that her time is her life.

Pneumonitis, a lung inflammation, often appears months after the cancer treatment that sparked it.

The immunotherapy drug Opdivo (nivolumab) prolonged survival in patients with advanced renal cell carcinoma more effectively than a comparator drug, Afinitor (everolimus), in a recent phase 3 study.